



Date: 16th January, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051
Scrip Code: 539872	Symbol: BAJAJHCARE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015

We wish to inform you that Bajaj Healthcare Limited, has received an exclusive right for manufacturing, distribution & sales of the finished formulation of the Product Magnesium L Threonate (Magtein®) in India from the rights holder, Threotech LLC.

Threotech LLC has granted Bajaj Healthcare Limited the licensing rights to manufacture finished formulation of Magnesium L Threonate (Magtein®) along with the rights to enter into marketing collaborations with leading branded pharmaceutical firms for the Indian market.

The press release in this regard, being issued by the Company is hereby submitted for your information.

Further, we hereby confirm that none of the promoter/ promoter group / group companies have any interest in the entity(ies) from whom the contract is received and the contract does not fall within the purview of related party transactions.

Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 & the Company's code of Internal Procedures and Conduct for Regulating, monitoring & reporting of trading in securities, the Trading window for dealing in securities of the Bajaj Healthcare Limited shall continue to remain closed for all the Directors and Designated Employees in terms of our earlier disclosure dated 27th December 2024.

Kindly acknowledge and take the same on record.

Thanking You,

**For and Behalf of Board of Directors of
Bajaj Healthcare Limited**

**Apurva Bandivadekar
Company Secretary & Compliance Officer**

BAJAJ HEALTHCARE LTD

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892



Investor Release

Bajaj Healthcare Limited receives new contract for manufacturing, marketing and selling of the product Magnesium L Threonate (Magtein®) in the Indian Market

Mumbai, 16th Jan 2025: Bajaj Healthcare Limited announced today that it has received exclusive rights for manufacturing, distribution & sales of the finished formulation of the Product Magnesium L Threonate (Magtein®) in India from the rights holder, Threotech LLC.

Threotech LLC has granted Bajaj Healthcare Limited the licensing rights to manufacture finished formulation of Magnesium L Threonate (Magtein®) along with the rights to enter into marketing collaborations with leading branded pharmaceutical firms for the Indian market.

Bajaj Healthcare Limited will therefore have the rights to manufacture/ market/ distribute/co-market in the Indian market for Magnesium L Threonate (Magtein®). The Company is already supplying the API Magnesium L Threonate (Magtein®), to the patent holder in United States of America.

The API is supplied by Bajaj Healthcare Ltd. for the brand Magtein® in the United States of America as an exclusive arrangement. The brand Magtein® by Threotech LLC has a sales value of approx. USD 438 million.

Speaking at the occasion Mr. Anil Jain, Managing Director, Bajaj Healthcare Limited, said - “Our collaboration with Threotech LLC has taken an exciting step forward after receiving licensing rights for manufacturing, marketing and selling their innovative product, Magtein®, in India. With our strong domestic presence and proven manufacturing & distribution expertise, we are well-positioned to unlock the product’s full potential in the Indian market. This development reaffirms our position as a trusted partner to our international clients and underscores our ability to seamlessly integrate manufacturing & quality excellence with strategic market outreach.”

About Bajaj Healthcare Ltd:

Bajaj Healthcare Limited a leading Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993. It specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.



Contact Details

Bajaj Healthcare Ltd	Investor Relations: Orient Capital
	
CIN: L99999MH1993PLC072892	Mr. Irfan Raeen +91 9773778669/ Irfan.raeen@linkintime.co.in
Name: Mr. Anil Jain, MD	
Email: : investors@bajajhealth.com	Ms. Prachi Ambre +91 8355985370/ Prachi.ambre@linkintime.co.in

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.